Zeteletinib hemiadipate

Zeteletinib hemiadipate (BOS-172738; DS-5010) is a potent and selective oral RET kinase inhibitor with nanomolar activity, showing high selectivity over VEGFR2. It effectively targets wild-type RET, gatekeeper mutants (V804M/L), and the oncogenic M918T variant. This compound has demonstrated significant antitumor efficacy in both cellular assays and in vivo models, supporting its investigation in RET-driven cancers.